Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.59 |
| ▸ | CDK2 | P24941 | 11/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116749 | 0.89 | GSK3B (0.76) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL13116758 | 0.89 | CDK2 (0.74) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12953067 | 0.86 | CDK2 (0.72) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12952881 | 0.84 | GSK3B (0.79) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953179 | 0.79 | CDK2 (0.80) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL14301219 | 0.79 | CDK2 (0.64) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12954309 | 0.79 | GSK3B (0.56) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12953040 | 0.78 | CDK2 (0.76) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12953002 | 0.78 | GSK3B (0.79) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12953026 | 0.77 | CDK2 (0.81) | GSK3BCDK2CCNE1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |